^
    Back
    Association details:
    Biomarker:TSPYL1 P62S
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Clin Pharmacol Ther
    Title:

    TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer

    Excerpt:
    Data from a prospective clinical trial of 87 metastatic castration‐resistant prostate cancer patients treated with abiraterone acetate/prednisone showed that the variant SNP genotype (A) was significantly associated with worse response and progression‐free survival.
    Secondary therapy:
    prednisone
    DOI:
    https://doi.org/10.1002/cpt.907
    Trial ID:
    PROMOTE